Meliglix 50 Mg

Sitagliptin Hydrochloride, the active ingredient in Meliglix, is a dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a 50 mg tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used as part of a comprehensive treatment plan.

GNH USA supplies Meliglix as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality-assured medicines for diabetes care and supporting healthcare providers with consistent product availability.

Sitagliptin Hydrochloride is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): reduces blood glucose levels and HbA1c when used alone. - Type 2 diabetes mellitus (combination with metformin): enhances glycaemic control alongside metformin therapy. - Type 2 diabetes mellitus (combination with sulfonylureas): provides additional glucose lowering when added to sulfonylurea treatment.

Sitagliptin Hydrochloride may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient, often mild. - Upper respiratory tract infection: symptoms of cough and congestion. - Nausea: occasional stomach upset. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including anaphylaxis, angioedema, or skin rash. - Joint pain: unexplained arthralgia that may be disabling. - Hepatic injury: elevated liver enzymes or hepatitis. - Bullous pemphigoid: rare autoimmune skin disorder.

Before initiating therapy, clinicians should consider several safety factors. - Renal function: dose adjustment may be required in patients with impaired renal function. - Hepatic function: monitor liver enzymes in patients with existing liver disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pancreatitis: be alert for persistent abdominal pain or vomiting. - Cardiovascular: use with caution in patients with heart failure. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Sitagliptin Hydrochloride can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Insulin: combined use may increase risk of hypoglycaemia. - Sulfonylureas: concurrent therapy can potentiate hypoglycaemic episodes. - Strong CYP3A4 inhibitors: may raise sitagliptin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may reduce the glucose‑lowering effect of sitagliptin. - Rifampin: can lower sitagliptin levels, diminishing efficacy. - ACE inhibitors: monitor renal function when used together.